Aleta’s pipeline targets diverse antigens and indications. Our ability to broadly target cancers illustrates the facile and modular characteristics of the underlying technology. As each program advances in the clinic the portfolio is extended, building upon the first module or concept. For example, the Her2 program leads naturally to the program that targets both Her2 and B7H3, while the biologic program to enhance CAR-CD19 therapy leads to a similar approach to enhance CAR-BCMA therapy. Near-term execution of carefully constructed clinical trials, led by top cell therapy clinicians, will result in efficient translation of our technology into practice, while supporting a growing portfolio.